HCWB vs. OCUP, NXTC, GANX, EYEN, CASI, VYNE, NBRV, UNCY, AADI, and XLO
Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Ocuphire Pharma (OCUP), NextCure (NXTC), Gain Therapeutics (GANX), Eyenovia (EYEN), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Nabriva Therapeutics (NBRV), Unicycive Therapeutics (UNCY), Aadi Bioscience (AADI), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
HCW Biologics (NASDAQ:HCWB) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.
3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are owned by institutional investors. 45.3% of HCW Biologics shares are owned by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Ocuphire Pharma received 28 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 68.00% of users gave Ocuphire Pharma an outperform vote.
In the previous week, Ocuphire Pharma had 9 more articles in the media than HCW Biologics. MarketBeat recorded 15 mentions for Ocuphire Pharma and 6 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.09 beat Ocuphire Pharma's score of -0.31 indicating that HCW Biologics is being referred to more favorably in the media.
Ocuphire Pharma has a consensus price target of $18.75, indicating a potential upside of 1,012.76%. Given Ocuphire Pharma's higher possible upside, analysts plainly believe Ocuphire Pharma is more favorable than HCW Biologics.
Ocuphire Pharma has a net margin of -59.44% compared to HCW Biologics' net margin of -697.53%. Ocuphire Pharma's return on equity of -24.57% beat HCW Biologics' return on equity.
HCW Biologics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Ocuphire Pharma has higher revenue and earnings than HCW Biologics. Ocuphire Pharma is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
Ocuphire Pharma beats HCW Biologics on 12 of the 18 factors compared between the two stocks.
Get HCW Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCW Biologics Competitors List
Related Companies and Tools
